^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Epithelial Ovarian Cancer

    Associations

    News

    Trials
    18h
    TSL-B2276-1-01: A Study of STRO-002 in Chinese Adults With Epithelial Ovarian Cancer and Other Advanced Malignant Solid Tumors (clinicaltrials.gov)
    P1/2, N=19, Completed, Tasly Pharmaceutical Group Co., Ltd | Recruiting --> Completed | N=132 --> 19 | Trial completion date: Dec 2027 --> Dec 2025 | Trial primary completion date: Dec 2026 --> Jun 2025
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
    |
    HER-2 negative
    |
    luveltamab tazevibulin (STRO-002)
    2d
    Unmasking FCGR2B as a high-grade serous ovarian cancer specific marker of immune suppression and tumor progression through multi-omics mining. (PubMed, Transl Oncol)
    These findings delineate subtype-specific genetically informed protein-immune regulatory landscapes in EOC and identify FCGR2B as a key immunoregulatory and prognostic biomarker in HGSOC, suggesting FCGR2B as a potential therapeutic vulnerability that warrants further investigation.
    Journal
    |
    FCGR2B (Fc Fragment Of IgG Receptor IIb)
    3d
    Immunotherapy advancements in high-grade serous ovarian cancer: From promise to practice. (PubMed, Crit Rev Oncol Hematol)
    ADCs are leading current clinical advances. Future priorities include biomarker-driven trial designs, strategic treatment sequencing, and innovative combination strategies to maximize therapeutic benefit while minimizing toxicity.
    Review • Journal • Tumor mutational burden • PARP Biomarker • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden) • HRD (Homologous Recombination Deficiency) • FOLR1 ( Folate receptor alpha )
    |
    PD-L1 expression • HRD
    4d
    QPT-ORE-004: A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer. (clinicaltrials.gov)
    P2, N=10, Active, not recruiting, CanariaBio Inc. | Trial completion date: Jul 2025 --> Dec 2027 | Trial primary completion date: Mar 2025 --> Dec 2026
    Trial completion date • Trial primary completion date • Platinum sensitive
    |
    MUC16 (Mucin 16, Cell Surface Associated)
    |
    Zejula (niraparib) • OvaRex (oregovomab)
    5d
    Vascular Protection of Poly(ADP-ribose) Polymerase Inhibitors in the Combination Therapy With Vascular Endothelial Growth Factor Signaling Pathway Inhibitors. (PubMed, Rev Cardiovasc Med)
    Clinically, PARPIs, in combination with anti-angiogenic therapies, not only show efficacy as monotherapies in epithelial ovarian cancer but also mitigate hypertension induced by anti-angiogenic agents. This review consolidates recent advancements in understanding the dual therapeutic potential of PARP inhibition, encompassing both antineoplastic and cardioprotective effects.
    Review • Journal • BRCA Biomarker • PARP Biomarker
    |
    BRCA (Breast cancer early onset)
    |
    BRCA mutation
    5d
    FLORA-4: Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery (clinicaltrials.gov)
    P3, N=615, Active, not recruiting, CanariaBio Inc. | Trial primary completion date: Mar 2026 --> Dec 2026
    Trial primary completion date
    |
    carboplatin • paclitaxel • OvaRex (oregovomab)
    6d
    QPT-ORE-006: Oregovomab Plus Chemotherapy in Neo-adjuvant Setting in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer (clinicaltrials.gov)
    P2, N=88, Active, not recruiting, CanariaBio Inc. | Trial primary completion date: Jan 2026 --> Oct 2026
    Trial primary completion date
    |
    carboplatin • paclitaxel • OvaRex (oregovomab)
    6d
    TREVI-OC-01: AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer (clinicaltrials.gov)
    P3, N=289, Recruiting, AstraZeneca | N=46 --> 289
    Enrollment change • Platinum resistant
    |
    BRCA (Breast cancer early onset)
    |
    BRCA mutation
    |
    paclitaxel • pegylated liposomal doxorubicin • Elahere (mirvetuximab soravtansine-gynx) • topotecan • torvutatug samrotecan (AZD5335)
    6d
    Regulatory effects of miRNA in epithelial ovarian cancer patients: A case-control study from Eastern India. (PubMed, J Cancer Res Ther)
    The study reveals the overexpression of miR-200a, miR-200b, and miR-200c in EOC patients. MiR-200a and miR-200b expression was correlating with early stage, while miR-200c emerged as a prognostic marker, correlating with cancer severity. This suggests regulatory role; however, further investigation into epithelial-to-mesenchymal transition-related factors is warranted to have a deeper understanding of the differential expression of miRNAs. The study underscores the diagnostic potential of serum miRNAs in EOC and the need for a reliable early detection method.
    Journal
    |
    MIR200B (MicroRNA 200b) • MIR200C (MicroRNA 200c) • MIR200A (MicroRNA 200a)
    6d
    Women with suspected diagnosis of ovarian cancer in Ghana: how much do we know about them? (PubMed, Front Oncol)
    Most women with ovarian tumours were young, and a significant proportion had benign tumours, highlighting the need for a more thorough diagnostic assessment. Improved gynaecological ultrasound scanning, access to intraoperative pathology consultation and molecular testing will be essential for guiding ovarian cancer care in Ghana.
    Journal
    |
    MUC16 (Mucin 16, Cell Surface Associated)
    6d
    Bioinformatics and experimental analysis revealed the cancer-promoting role of NCAPG2 in epithelial ovarian cancer. (PubMed, Front Oncol)
    Clinical specimens have confirmed that NCAPG2 is highly expressed in EOC tissues and is closely related to the clinical stage. High expression of NCAPG2 can promote the progression of EOC and may serve as a potential novel therapeutic target for EOC.
    Journal • IO biomarker
    |
    CAPG (Capping Actin Protein, Gelsolin Like) • NCAPG2 (Non-SMC Condensin II Complex Subunit G2)
    6d
    Effect of first-line poly(ADP-ribose) polymerase inhibitor on second-line platinum-based chemotherapy in epithelial ovarian cancer. (PubMed, J Gynecol Oncol)
    First-line PARP inhibitor maintenance therapy may reduce the efficacy of subsequent platinum-based chemotherapy, potentially inducing platinum resistance. These findings highlight the need to reconsider treatment strategies and predictive biomarkers for second-line therapy following PARP inhibitor exposure in relapsed EOC.
    Journal • PARP Biomarker
    |
    HRD (Homologous Recombination Deficiency)
    |
    HRD